Pathway Bioventures

United Statespathwaybioventures.com

Pathway Bioventures is a venture capital firm based in the United States, investing in Healthcare & Life Sciences, Software & Developer Tools and Genomics & Molecular Biology, 4 tracked investments.

View Full Profile Website

Investments Tracked

See full portfolio →

About Pathway Bioventures

Pathway Bioventures is a venture capital firm headquartered in the United States. We have recorded 4 investments for Pathway Bioventures to date.

Sector activity concentrates in Healthcare & Life Sciences, Software & Developer Tools, Genomics & Molecular Biology and Gene Therapy. Coverage extends to 8 sectors in total. Participation spans Seed and Series C+ rounds.

Focuses on early-stage healthcare and life science companies in the US. Aims to invest in innovative therapeutic and diagnostic technologies.

Investment Focus

Stage Focus

seedseries-c-plus

Sectors

Healthcare & Life SciencesSoftware & Developer ToolsGenomics & Molecular Biologygene therapyPersonalized MedicinePharmaceutical Developmentpharmaceutical-developmentrenal diseases

Investment Thesis

Focuses on early-stage healthcare and life science companies in the US. Aims to invest in innovative therapeutic and diagnostic technologies.

Team

Daniel JacobsFounder & Managing Partner

Daniel founded Pathway Bioventures in 2018 to accelerate the growth of groundbreaking early-stage life sciences companies. He leads Pathway’s operations and investment activities including the identification of new opportunities, diligence,…

Matt MartinPartner

As a Partner at Pathway Bioventures, Matt seeks out opportunities where investment can efficiently create significant value and bring new scientific discoveries to the clinic and improve patients' lives.

Jacob SegilVenture Partner

Jacob is a Research Professor in Mechanical Engineering as well as the Managing Director of the Center for Translational Research at University of Colorado Boulder.

Marta NewStrategic Advisor

Marta is a founder and CEO of Radyus Research, a collaborative research organization specializing in preclinical drug development.

David HardwickeInvestment Consultant

David is a biotechnology professional with a background in technology commercialization, program management, and drug development with prior positions at Novartis Gene Therapies and NK-cell therapy developer ONK Therapeutics.